Reported value$37.7M2,045,440 shares at $18.41
For this personUnusual1 buy · 0 sales on file
Similar buys beat S&P46%9,298 cases · all buys 46%
Worth a closer look
- Open-market purchase with their own money (Form 4 code P), not a grant or option exercise.
- Raised their own holding by 43%.
Reasons for caution
- Bought by a 10% owner or investment firm, whose reasons often differ from an executive's.
- Held indirectly (a trust, fund or family entity), so the economic owner isn't only the named insider.
- Similar past buys beat the S&P 500 only 46% of the time (9,298 cases); the typical one trailed it by 1.3%.
What happened after this filing
7 days
Pending
due Nov 3
30 days
Pending
due Nov 26
90 days
Pending
due Jan 25
Insider Twins: past buys with the same traits
1 insider buying · no CEO or CFO
GME Dec 21, 2020 +1183.4% vs S&PKXIN Jul 21, 2020 +836.6% vs S&PAGL Mar 3, 2026 +541.0% vs S&PRPGL Mar 6, 2026 -107.3% vs S&PADTX Apr 23, 2026 -105.7% vs S&PAVTX May 24, 2023 -103.9% vs S&PWhat we couldn't check
- Why they traded. Filings don't say, and we don't guess.
- Company news after the filing, and any private terms.
Summary
Venrock Healthcare Capital Partners Iii, L.P. (a 10% owner) bought $38M of LYCA at about $18.41 between Oct 23, 2026 and Oct 27, 2026, reported to the SEC on Oct 27, 2026. Buys like this beat the S&P 500 46% of the time since 2020, against 46% for all insider buys. We found 2 points that make it worth a closer look and 3 reasons for caution. History, not a prediction.
Sources
Original SEC Form 4 ↗ LYCA stock page
Venrock Healthcare Capital Partners Iii, L.P.'s record How the rules work
Following. We'll keep this page updated; see everything you follow. Want an email when the 30 and 90-day results land? Use the LYCA alerts below.
Written by fixed rules from SEC filings and our measured history, not by an AI model. Public data only. History, not a prediction, and not investment advice.